Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: (no name provided) who wrote (881)	6/30/1997 8:25:00 PM
From: Zirdu	of 6136

No name and David S.: Here's a response from LMoss of the Motley Fool AGPH board regarding the Vertex/Glaxo drug: Subj: Estimated filing date for GLX/VRTX PI Date: 30 Jun 1997 17:10:37 EDT From: LMoss Message-ID: <19970630211001.RAA05792@ladder02.news.aol.com> My "Extreme sports" post was reposted on the SI Agouron thread, and two people there said that the estimated date for the NDA filing of the Glaxo/Vertex protease inhibitor was later this year, not December 1998 as I had indicated. One wondered where I got my information. This particular bit of information comes from Glaxo. It is now guiding analysts to expect the filing in December 1998. This was reported by Smith Barney drug company analyst Christina Heuer in her RxScrips report, #SF06E208, June 18, 1997, p.11. It was reconfirmed by her in discussions with Glaxo on June 27, 1997. Glaxo will not comment on whether this is a delay or if any problems have arisen in the clinical trials, but it is most definitely not encouraging analysts to expect a filing before December 1998. LMoss

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next